

Alzheimer's Disease (AD)

## A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT02353598 GN29632

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This randomized, placebo-controlled, double-blind, parallel-arm study will evaluate the safety and tolerability of at least two dose levels of intravenous (IV) crenezumab in 24-72 participants with mild to moderate Alzheimer disease (AD) (mini-mental state examination [MMSE] 18 to 28 points, inclusive). An optional open-label extension (OLE) will be offered after the completion of initial double-blind stage.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT02353598 GN29632**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=50 Years & <= 90 Years

**Healthy Volunteers**  
No

---